Occult Primary
David S. Ettinger, Mark Agulnik, Justin Cates et al. · Journal of the National Comprehensive Cancer Network · 2011
Occult primary tumors, or cancers of unknown primary (CUPs), are defined as histologically proven metastatic malignant tumors whose primary site cannot be identified during pretreatment evaluation. They have a wide variety of clinical presentations and a poor prognosis in most patients. Patients with occult primary tumors often present with general complaints, such as anorexia and weight loss. Clinical absence of primary tumor, early dissemination, aggressiveness, and unpredictability of metastatic pattern are characteristic of these tumors. Life expectancy is very short, with a median survival of 6 to 9 months. In most patients, occult primary tumors are refractory to systemic treatments, and chemotherapy is only palliative and does not significantly improve long-term survival. However, certain clinical presentations of these tumors are associated with a better prognosis. Special pathologic studies can identify subsets of patients with tumor types that are more responsive to chemotherapy. Treatment options should be individualized for this selected group of patients to achieve improved response and survival rates.
Cited by 60 works. doi:10.6004/jnccn.2011.0117 Open-access PDF
Authors
- David S. Ettinger
- Mark Agulnik
- Justin Cates
- Mihaela C. Cristea
- Crystal Shereen Denlinger
- Keith D. Eaton
- Panagiotis M. Fidias
- David S. Gierada
- Jon P. Gockerman
- Charles R. Handorf
- Renuka V. Iyer
- Renato Lenzi
- John E. Phay
- Asif Rashid
- Leonard B. Saltz
- Lawrence N. Shulman
- Jeffrey B. Smerage
- Gauri Rajani Varadhachary
- Jonathan S. Zager
- Weining Zhen
References
- Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases
- Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
- MicroRNAs accurately identify cancer tissue origin
- Diagnostic and therapeutic management of cancer of an unknown primary
- Treatment of Patients with Cancer of an Unknown Primary Site
- Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer
- Poorly Differentiated Neuroendocrine Carcinoma of Unknown Primary Site
- Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
- Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation
- Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.